Wishlist Please, enable Wishlist.
Log in / Sign in

Lost password?

Cart $0.00 0

No products in the cart.

Return To Shop
Shopping cart (0)
Subtotal: $0.00

Checkout

Free shipping over 49$
Air Purifier SpecialistAir Purifier Specialist
  • Shop
  • About Us
  • News, Reviews & Info
    • Latest News
    • Product Reviews
    • Tips and Information
  • Contact Us

CytoSorbents CEO to Discuss COVID-19 Pandemic and its CytoSorb® Treatment of Cytokine Storm in Cowen COVID-19 Series Conference Call Today

25 April 2020 /Posted byBarbara / 394

MONMOUTH JUNCTION, N.J., April 3, 2020 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD will participate in a conference call, in fireside chat format, with Dr. Joshua Jennings, MD, Managing Director and Senior Research Analyst of Equity Research at Cowen and Company, LLC today to discuss the COVID-19 pandemic and the role that CytoSorbents is playing to help treat patients.

CytoSorbents Corporation (NASDAQ: CTSO) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses with its flagship product, CytoSorb. CytoSorb is approved in the European Union and distributed in 58 countries worldwide. (PRNewsfoto/CytoSorbents Corporation)

CytoSorbents Corporation (NASDAQ: CTSO) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses with its flagship product, CytoSorb. CytoSorb is approved in the European Union and distributed in 58 countries worldwide. (PRNewsfoto/CytoSorbents Corporation)

Date and Time:  Today, April 3, 2020 at 1PM EDT

Registration and weblink: 

https://www.netroadshow.com/conferencing/login?show=30cabb25&confId=15766

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 58 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® has been used in more than 80,000 human treatments to date.

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of nearly $29 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM), the U.S. Army, U.S. Special Operations Command (USSOCOM), the U.S. Air Force, Air Force Material Command (USAF/AFMC) and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including CytoSorb-XL™, HemoDefend™, VetResQ™, K+ontrol™, ContrastSorb, DrugSorb, and others.  For more information, please visit the Company’s websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 5, 2020, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements, particularly in light of the current coronavirus pandemic, where businesses can be impacted by rapidly changing state and federal regulations, as well as the health and availability of their workforce. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws. 

Please Click to Follow Us on Facebook and Twitter

CytoSorbents Contact: 

Amy Vogel

Investor Relations

(732) 398-5394

avogel@cytosorbents.com

Investor Relations Contact: 

Jeremy Feffer

LifeSci Advisors

917-749-1494

jeremy@lifesciadvisors.com

Public Relations Contact:

Eric Kim 

Rubenstein Public Relations

212-805-3052

ekim@rubensteinpr.com  

Cision

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/cytosorbents-ceo-to-discuss-covid-19-pandemic-and-its-cytosorb-treatment-of-cytokine-storm-in-cowen-covid-19-series-conference-call-today-301035041.html

SOURCE CytoSorbents Corporation

Read More

Share Post
  • Twitter
  • Facebook
  • Pinterest
  • Mail to friend
  • Linkedin
  • Whatsapp
  • Skype
The post-coronavirus office: m...
CytoSorb® Used to Treat More t...

About author

About Author

Barbara

Other posts by Barbara

Related posts

Pinecrest Nursing Home, hard hit by COVID-19, says outbreak is over

14 May 2020
Pinecrest Nursing Home, hard hit by COVID-19, says outbreak is over - newhamburgindependent.ca Continue reading

Pangolins May Not Have Been The Intermediary Host of SARS-CoV-2 After All

14 May 2020
TESSA KOUMOUNDOUROS 14 MAY 2020 Understanding the origins of the virus causing COVID-19 is one of the key questions scientists are trying to resolve while... Continue reading
Convalescent plasma is safe to treat COVID-19: nationwide study
Latest News
Read more

Convalescent plasma is safe to treat COVID-19: nationwide study

14 May 2020
The most comprehensive national study to date has found that convalescent plasma appears to be safe to use on COVID-19 patients, a promising development in... Continue reading
Studies provide more evidence that coronavirus damages the kidneys
Latest News
Read more

Studies provide more evidence that coronavirus damages the kidneys

14 May 2020
One-third of hospitalized coronavirus patients have kidney damage and high levels of the virus in the organs, two studies revealOne study found that 36.6% of... Continue reading
New York Sent Recovering Coronavirus Patients to Nursing Homes: ‘It Was a Fatal Error’
Latest News
Read more

New York Sent Recovering Coronavirus Patients to Nursing Homes: ‘It Was a Fatal Error’

14 May 2020
In late March, Dottie Hickey got a call from Luxor Nursing & Rehabilitation at Mills Pond, the nursing home where her sister lived. The 79-year-old... Continue reading

Comments are closed

Recent Posts

  • Pinecrest Nursing Home, hard hit by COVID-19, says outbreak is over
  • Pangolins May Not Have Been The Intermediary Host of SARS-CoV-2 After All
  • Convalescent plasma is safe to treat COVID-19: nationwide study
  • Studies provide more evidence that coronavirus damages the kidneys
  • New York Sent Recovering Coronavirus Patients to Nursing Homes: ‘It Was a Fatal Error’

Recent Comments

    © Copyright 2013      Air Technology Solutions Canada

    Powered by  Barbara Blackett Consulting
    • Shipping and Returns
    • Privacy Policy
    • Terms of Use